Hospitalization and mortality rates of malignant prostatic neoplasms in Brazil
A cross-sectional study from 2008 to 2018
DOI:
https://doi.org/10.1590/Keywords:
Prostate cancer, Brazilian epidemiology, Hospitalization rate, Mortality rate, Public health careAbstract
Prostate cancer (PCa) is a highly prevalent condition among men worldwide, resulting in reduced quality of life and increased costs to health systems due to hospitalization and death. This study aimed to explore and understand the evolution of PCa in Brazil from 2008 to 2018. Data were obtained from the National Health System Department of Informatics (DATASUS) using code C61 for malignant prostatic neoplasms. We presented the hospitalization and mortality rates in a temporal-, regional- and age-dependent manner. From 2008 to 2018, a year-dependent increase in hospital admissions due to PCa was reported in Brazil, in which the Southeast region showed the highest prevalence. Men aged ≥80 and those 70-79 years old had similar hospitalization rates, followed by men aged 60-69, 50-59, 40-49 and 30-39 years old. Similarly, an increase in deaths due to PCa was reported during this period, with the highest rates seen in the Southeast. Men aged ≥80 years had higher mortality rates, followed by those aged 70-79, 60-69, 50-59, 40-49 and 30-39 years old. The results obtained indicate an age- and region-dependent increase in PCa morbidity and mortality in Brazil overtime and may contribute to the ongoing discussion on the role and future perspective of the health care system in Brazil.
Downloads
References
Albuquerque MV, Viana ALD, Lima LD, Ferreira MP, Fusaro ER, Iozzi FL. Regional health inequalities: Changes observed in Brazil from 2000-2016. Cien Saude Colet. 2017; 22(4):1055-1064.
Alemozaffar M, Regan M, Cooperberg M, Wei JT, Michslski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011; 306(11):1205-14.
Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, et al. Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer Statement from the DEGRO working group on prostate cancer. Strahlentherapie und Onkol. 2020; 196(2):109-116.
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors - A systematic review. Eur Urol. 2023; 84(2):191-206.
Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005; 66(2):286-294.
Brazil, Ministry of Health. DATASUS. Mortality Information System (SIM) and Hospital Information System (SIH) [Internet]. Brasilia (DF): Ministry of Health 2019. [cited 2019 Nov 11]. Available in: Available in: http://www2.datasus.gov.br
Brazil, Ministry of Health. Diretrizes diagnósticas e terapêuticas do adenocarcinoma de próstata[Internet]. Brasilia (DF): Ministry of Health 2016. Available in: http://antigo-conitec.saude.gov.br/images/Protocolos/DDT/DDT_AdenocarcinomadeProstata_.pdf
» http://antigo-conitec.saude.gov.br/images/Protocolos/DDT/DDT_AdenocarcinomadeProstata_.pdf
Calmasini FB, Silva FH, Alexandre EC, Rodrigues RL, Barbosa AP, Ferrucci DL, et al. Implication of Rho-Kinase and Soluble Guanylyl Cyclase Enzymes in Prostate Smooth Muscle Dysfunction in Middle-Aged Rats. Neurourol Urodyn. 2017; 36(6):589-596.
Candiago RH, Abreu PB De. Use of DATASUS to evaluate psychiatric inpatient care patterns in Southern Brazil. Rev Saude Publica. 2007; 41(5):821-9.
Castro HAS, Iared W, Shigueoka DC, Mourao JE, Ajzen S. Contribution of PSA density in the prediction of prostate cancer in patients with PSA values between 2.6 and 10 ng/mL. Radiol Bras. 2011; 44(4):205-209.
Cetin B, Ozet A. The Potential for Chemotherapy-Free Strategies in Advanced Prostate Cancer. Curr Urol. 2019; 13(2):57-63.
Chen Y, Fan Y, Yang Y, Jin J, Zhou L, He Z, et al. Are prostate biopsies necessary for all patients 75 years and older? J Geriatr Oncol. 2018; 9(2):124-129.
de Vries E, Buitrago G, Quitian H, Wiesner C, Castillo JS. Access to cancer care in Colombia, a middle-income country with universal health coverage. J Cancer Policy. 2018; 15(Part B):104-12.
Duncan ME, Goldacre MJ. Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations. BJU Int. 2011; 107(1):40-45.
Fonseca PB, Albuquerque PC, Saldanha RF, Zicker F. Geographic accessibility to cancer treatment in Brazil: A network analysis. The Lancet Regional Health. 2021; 7:100153.
Ghatak S, Ho SM. Age-Related Changes in the Activities of Antioxidant Enzymes and LipidPeroxidation Status in Ventral and Dorsolateral Prostate Lobes of Noble Rats. Biochem Biophys Res Commun. 1996; 222(2):362-367.
Guo T, Wang X, Fu H, Tang Y, Meng B, Chen C. Early diagnostic role of PSA combined miR-155 detection in prostate cancer. Eur Rev Med Pharmacol Sci. 2018; 22(6):1615-1621.
Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, et al. Secular trends in prostate cancer mortality , incidence and treatment : England and Wales , 1975-2004. BJU Int . 2008; 101(5):547-555.
Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020; 17(1):28-40.
Kunath F, Jensen K, Pinart M, Kahlmeyer A, Schmidt S, Price CL, et al. Early versus deffered standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2019; 6(6):CD003506.
Lakkur S, Goodman M, Bostick RM, Citronberg J, McClellan W, Flanders WD, et al. Oxidative balance score and risk for incident prostate cancer in a prospective U.S. cohort study. Ann Epidemiol. 2014; 24(6):475-478.e4.
Li J, Siegel DA, King JB. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014. Ann Epidemiol . 2018; 28(5):328-330.
Lopes TDS, Fritoli RB, Silva FH, Calmasini FB. Aging-associated prostate smooth muscle hypercontractility in rats. Braz J Pharm Sci. 2022; 58:e21063.
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis. JAMA Oncol. 2015; 1(9):1261-9.
McMahon DM, Burch JB, Hébert JR, Hardin JW, Zhang J, Wirth MD, et al. Diet-related inflammation and risk of prostate cancer in the California Men’s Health Study. Ann Epidemiol . 2019; 29:30-38.
Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen supression in the treatment od advanced prostatic cancer. Cochrane Database Syst Rev . 2002; (1):CD003506.
Nogueira L, Corradi R, Eastham JA. Prostatic Specific Antigen for Prostate Cancer detection. Int Brazilian J Urol. 2009; 35(5):521-531.
Oliveira MG, Alexandre EC, Bonilla-Becerra SM, Bertollotto GM, Justo AFO, Monica FZ, et al. Autonomic dysregulation at multiple sites is implicated in age associated underactive bladder in female mice. Neurourol Urodyn . 2019; 38(5):1212-1221.
Parreira LB, Vitorino PV, Jardim PCBV, Sousa ALL, Jardim TV, Sousa WM, et al. Comparison Between Supervised and Partly Supervised Cardiac Rehabilitation Protocols in Hypertensive Patients: A Randomized Controlled Trial. Curr Hypertens Rev. 2018; 14 (2):161-169.
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89.
Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. What Do Prostate Cancer Patients Die Of? Oncol. 2011; 16(2):175-181.
Sanda MG, Dun RL, Michalski J, Sandler HM, Northhouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358(12):1250-1261.
Santo AH. Causas mal definidas de morte e óbito sem assistência. Rev Ass Med Bras. 2008; 54(1):23-28.
Schneider L, Su LJ, Arab L, Bensen JT, Farnan L, Fontham ETH, et al. Dietary patterns based on the Mediterranean diet and DASH diet are inversely associated with high aggressive prostate cancer in PCaP. Ann Epidemiol . 2019; 29:16-22.e1.
Steffen RE, Trajman A, Santos M, Caetano R. Population screening for prostate cancer: more risks than benefits. Physis. 2018; 28(2):1-12.
Tang J, Zhong L, Paoli C, Paciorek A, Carroll P, Wilson L. Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. Am J Mens Health. 2019; 13(2):1557988319835326.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advance prostate cancer. N Engl J Med . 2004; 351(15):1502-12.
Vaz CV, Marques R, Maia CJ, Socorro S. Aging-associated changes in oxidative stress, cell proliferation, and apoptosis are prevented in the prostate of transgenic rats overexpressing regucalcin. Transl Res. 2015; 166(6):693-705.
Xia X, Jiang Q, Mcdermott J, Dong J. Aging and Alzheimer ’ s disease : Comparison and associations from molecular to system level. Aging Cell. 2018; 17:1-14.
Yahya N, Sukiman NK, Suhaimi NA, Azmi NA, Manan HA. How many roads must a Malaysian walk down? Mapping the accessibility of radiotherapy facilities in Malaysia. PLoS ONE. 2019; 14(3):e0213583.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
